Topical Vitamin C for Treatment of Basal Cell Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04279535|
Recruitment Status : Completed
First Posted : February 21, 2020
Last Update Posted : February 21, 2020
|Condition or disease||Intervention/treatment||Phase|
|Basal Cell Carcinoma||Drug: Topical Ascorbic Acid||Early Phase 1|
Skin cancer is the most common cancer in the United States, with more people diagnosed each year than all other cancers combined (1). Basal cell cancer is the most common form with an estimated 4.3 million cases diagnosed annually (2,3). Costs of treating this cancer in the U.S. are estimated at $4.8 billion annually (4). Task force consensus guidelines suggest Mohs surgery as the treatment of choice, and as the single most precise and effective treatment method (5). However, cost and issues of cosmesis are principal disadvantages.
To evaluate efficacy of a therapeutic regimen in treating basal cell cancer, consisting of 30% ascorbic acid in 95% dimethylsulfoxide topically applied at home by patients twice a day for 8 weeks.
Design, Setting, and Participants
This case series of 4 patients with 6 lesions was conducted after biopsy proven diagnosis of basal cell cancer. All 4 patients sought initial non-surgical treatment. All 4 had an appointment set for Mohs surgery 10 wks after study enrollment, so in the event of treatment failure no further delay in definitive treatment would occur. Three patients were female, 1 male, and all were over the age of 50.
An 8 wk therapeutic regimen of topical 30% (w/v) ascorbic acid, 95% (v/v) dimethylsulfoxide, and 5% (v/v) distilled water applied twice daily at home.
Main Outcomes and Measures
Number of lesions out of a total of six that were cancer free after 8 wks of treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Topical Ascorbic Acid for Treatment of Basal Cell Carcinoma|
|Actual Study Start Date :||March 1, 2018|
|Actual Primary Completion Date :||March 1, 2019|
|Actual Study Completion Date :||June 1, 2019|
Experimental: Treatment group
Participants applied topical solution of ascorbic acid twice daily for 8 weeks
Drug: Topical Ascorbic Acid
Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
- Lesion Resolution [ Time Frame: 8 weeks ]Number of lesions resolved out of total of 6 treated.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04279535
|United States, Idaho|
|Center for Biomedical Research,Inc.|
|Boise, Idaho, United States, 83706|
|Principal Investigator:||Briant Burke, MD||CBR,Inc.|